Leuject (Cladribine)

Cladribine is a purine nucleoside analog that enters lymphocytes and is phosphorylated inside the cell. The phosphorylated form incorporates into DNA, inhibiting DNA synthesis and leading to selective apoptosis of B and T lymphocytes, thereby reducing the autoimmune response responsible for multiple sclerosis lesions.

The dosing regimen for Leuject is determined by the prescribing physician based on the patient’s clinical profile, disease activity, and regulatory guidelines. Healthcare professionals tailor the dose and schedule to each individual, and patients should follow the prescriber’s instructions precisely.

Cladribine may pose risks to a developing fetus and to a nursing infant. It should only be used during pregnancy or lactation if the potential benefits justify the potential risks. Women of childbearing potential should discuss contraception and pregnancy planning with their healthcare provider before starting therapy.

To request Leuject, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain handling if required) and assist with import documentation.

Leuject (cladribine) differs from many other disease‑modifying therapies by providing short‑course oral‑like dosing that leads to sustained lymphocyte depletion, whereas agents such as interferons or dimethyl fumarate require continuous daily administration. Its efficacy in reducing relapse rates is comparable to other high‑efficacy options, but safety profiles and monitoring requirements vary, making individual patient factors important in therapy selection.

Leuject should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and ensure proper handling during transport.

Leuject is administered by subcutaneous injection. The injection is typically given by a healthcare professional in a clinical setting according to the prescribed schedule. Patients should be observed for any immediate reactions after the injection and instructed on post‑administration care.

The most serious risks include severe lymphopenia that can lead to opportunistic infections, reactivation of latent viruses such as herpes zoster, rare cases of malignancy, autoimmune hepatitis, and very rare neurological complications like progressive multifocal leukoencephalopathy. Patients should be monitored closely for signs of infection or abnormal laboratory results.

Leuject is contraindicated in patients with active severe infections, known hypersensitivity to cladribine or any excipients, and those who are pregnant unless the benefits outweigh the risks. Individuals with significant immunodeficiency or who are receiving other potent immunosuppressive therapies should avoid its use unless specifically directed by a specialist.